- Economy
- Education And Career
- Companies & Markets
- Gadgets & Technology
- After Hours
- Healthcare
- Banking & Finance
- Entrepreneurship
- Energy & Infra
- Case Study
- Video
- More
- Sustainability
- Web Exclusive
- Opinion
- Luxury
- Legal
- Property Review
- Cloud
- Blockchain
- Workplace
- Collaboration
- Developer
- Digital India
- Infrastructure
- Work Life Balance
- Test category by sumit
- Sports
- National
- World
- Entertainment
- Lifestyle
- Science
- Health
- Tech
Latest Articles in Healthcare
Gilead Prices COVID-19 Drug Remdesivir At $2,340 Per Patient In Developed Nations
Cipla's version is priced at less than 5,000 Indian rupees ($66.24), while Hetero Lab's version is priced at 5,400 rupees ($71.54).
Read More
Bharat Biotech Announces India's First COVID-19 Vaccine Candidate 'COVAXIN' With DCGI Approval For Human Clinical Trials
The indigenous, inactivated vaccine developed and manufactured in the company's Bio-Safety Level 3 (BSL-3) High Containment facility located in Genome Valley, Hyderabad.
Read More
Temasek-Led Investor Group In $250 Million Vaccine Bet On Biontech
The investors are in for an early reckoning because BioNTech has said it expects first clinical data on its COVID-19 vaccine development programme known as BNT162 this month or in July.
Read More
CanSino's COVID-19 Vaccine Candidate Approved For Military Use In China
China's Central Military Commission approved the use of the vaccine by the military on June 25 for a period of one year,
Read More
Japan's Takeda Expects $200 Million Operating Loss Related To Novartis' Xiidra Withdrawal
Takeda sold Xiidra to Novartis for $3.4 billion upfront and up to an additional $1.9 billion in potential milestone receipts.
Read More
Carlyle Group To Buy 20% Stake In Piramal Pharma For Over Rs 3,700 Cr
The capital raise will accelerate Piramal Pharma's organic and inorganic growth plans,
Read More
Vaccine Makers Face Biggest Medical Manufacturing Feat In History
J&J has partnered with the U.S. government on a $1 billion investment to speed development and production of its vaccine, even before it's proven to work.
Read More
Vaccine Alliance Finds Manufacturing Capacity For 4 Bln Doses Of Coronavirus Vaccines
CEPI has deployed up to $829 million so far in the search for a COVID-19 vaccine through partnerships with nine developers, with the hope that at least some will be successful.
Read More
India's Hetero Prices Experimental COVID-19 Drug Remdesivir At $71 Per 100 mg Vial
Fellow Indian drug firm Cipla Ltd had said on Tuesday that its own version of the antiviral drug remdesivir would be priced below Rs 5,000
Read More
India's Hetero Prices Experimental COVID-19 Drug Remdesivir At $71 Per 100 Mg Vial
India has approved the generic versions made by Cipla and Hetero for restricted emergency use in severe COVID-19 cases.
Read More
Inovio Gets $71 Million From U.S. Defense Dept For COVID-19 Vaccine Device
Inovio said a previous version of the device has been used in clinical trials to safely dose more than 2,000 patients
Read More
Cipla To Price Remdesivir Version For COVID-19 Under 5,000 Rupees
The expectations suggest sales of between $2 billion and $3 billion between 2020 and 2021 at a price of $1,000 to $2,000 per course, according to Jefferies analyst Michael Yee.
Read More
Pig Trial Of AstraZeneca's COVID-19 Vaccine Shows Promise With Two Shots
The researchers saw a marked increase in neutralising antibodies, which bind to the virus in a way that blocks infection," the Pirbright team said in a statement.
Read More
Sanofi Eyes Approval Of COVID-19 Vaccine By First Half Of 2021
There are currently no vaccines to prevent the coronavirus that has infected more than 9 million people and killed over 469,000 globally, and only a couple of medicines that have demonstrated benefit in hospitalized COVID-19 patients in clinical trials.
Read More
Sanofi Eyes Approval Of COVID-19 Vaccine By First Half Of 2021
Sanofi, which is hosting a virtual research and development event, and GSK had said in April the vaccine, if successful, would be available in the second half of 2021.
Read More